Evotec AG and The Mark Foundation for Cancer Research have entered into a research collaboration to discover and develop first-in-class therapeutics in oncology.    The collaboration, for an initial period of two years, is based on Evotec’s new proprietary drug discovery platform TargetAlloMod, which is focused on disrupting cell signalling via a novel mechanism of action. This approach is expected to deliver highly potent and more durable treatments for both clinically validated a...